Researchers: Merck's RotaTeq benefits unvaccinated children

Rates of hospitalization and emergency room visits among children due to rotavirus infection fell between 80% and 100% since the launch of Merck & Co.'s RotaTeq in 2006, according to studies from the CDC and Quest Diagnostics. The oral vaccine -- which is given to patients at ages 2 months, 4 months and 6 months -- also appeared to prevent the spread of the disease in older unvaccinated children, an expert on infectious diseases said.

View Full Article in:

Washington Post (tiered subscription model), The · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA